Background/Aim: Cysteine dioxygenase (CDO, E,C, 1.13.11.20) is the mai
n catabolic enzyme of cysteine, metabolising cysteine to cysteinesulph
inic acid, CDO abnormality has been implicated in a number of neurolog
ical and non-neurological diseases, with CDO deficiency possibly leadi
ng to excitotoxic damage to the brain and impaired Phase II metabolism
in the liver. Methods: Two novel anti-CDO antibodies raised against l
inear synthetic peptides corresponding to two distinct epitopes on the
22 kDa gene product of the CDO-I gene were used for immunohistochemis
try and Western blotting. These antibodies were characterised by their
ability to both block and precipitate CDO enzyme activity as well as
the ability of the respective antigenic peptides to absorb the antibod
ies and prevent the immunodetection of CDO. Results: The antibodies we
re found to detect the presence of a 68 kDa protein, which was subsequ
ently shown to be CDO. Distribution was found to be centrilobuIar and
did not alter when CDO was induced with cysteine or methionine; howeve
r, the intensity of staining increased, indicating an increase in the
levels of CDO in that region. Conclusions: These results suggest that
the 68 kDa Type II is the predominant isoform in vitro and in vivo and
that its centrilobular localisation may allow CDO to initate the prod
uction of sulphate and taurine for Phase II conjugation in the liver.